Titlebook: Cancer Therapeutics; Experimental and Cli Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 DNA.angiogenesis.cance

阻擋

Platinum Complexesncology physician. Interestingly, the chemical identity of cisplatin was first established in the mid-19th century (and known as Peyrone’s chloride) and, were it not for the well-documented serendipitous observations of Barnett Rosenberg while performing experiments investigating the effects of elec

鑒賞家

Dysarthria

Topoisomerase I Inhibitorss can also be coiled in circular DNA. This structure was called supercoiling. This finding was extended to linear DNA by Pettijohn and others (.). It is now known that practically all DNA in vivo is supercoiled (.). Because most of the functions of DNA require untwisting, the importance of the enzym

夸張

watertight,

Bis-Naphthalimidesicin and daunomycin, were originally isolated from natural sources, other compounds are synthetic organic molecules specifically designed as antineoplastic agents. Arcamone has classified these drugs on the basis of DNA interaction into:

Innovative

The Enediynesnostatin” and was thereafter determined to be an antimitotic agent (.). What followed was a long series of structural and chemical studies of neocarzinostatin, largely spearheaded by Goldberg and his colleagues (reviewed in 3), and culminating in clinical trials in Japan and the US (.). The Japanese

CLEFT

Matrix Metalloproteinase Inhibitorscribed invading tendrils of tumor tissue and the resulting destruction of bone and soft tissue, ascribed this behavior to an imbalance of the “Four Humors” resulting in a local excess of one of these, which he called “black bile” (.). This theory was later extended by Galen (131–203 .), who proposed

grudging

capillaries

Discovery of TNP-470 and Other Angiogenesis Inhibitors cells. Because many normal tissues contain stem cells that also proliferate rapidly (e.g., bone marrow, hair follicles, intestines), these types of agents often cause many side effects, and thus, their clinical effectiveness is limited. For this reason, many in the cancer field have begun to pursue

Afflict

Antisense Oligonucleotides, that have not been studied as potential drugs before and uses them to intervene in processes that, likewise, have not been studied as sites at which drugs might act. Although the field is still in its infancy, it has generated considerable enthusiasm because of the potential specificity of oligonu